Summit Global Investments Takes Position in Inogen, Inc. (NASDAQ:INGN)

Summit Global Investments bought a new stake in Inogen, Inc. (NASDAQ:INGN) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 11,646 shares of the medical technology company’s stock, valued at approximately $107,000.

Other large investors also recently modified their holdings of the company. Royce & Associates LP boosted its position in Inogen by 499.7% in the fourth quarter. Royce & Associates LP now owns 311,199 shares of the medical technology company’s stock worth $2,854,000 after purchasing an additional 259,308 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its position in shares of Inogen by 312.5% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 174,625 shares of the medical technology company’s stock valued at $1,694,000 after purchasing an additional 132,287 shares in the last quarter. Monaco Asset Management SAM raised its stake in shares of Inogen by 104.0% during the 4th quarter. Monaco Asset Management SAM now owns 76,500 shares of the medical technology company’s stock valued at $702,000 after purchasing an additional 39,000 shares during the period. Stokes Family Office LLC lifted its holdings in shares of Inogen by 29.0% in the fourth quarter. Stokes Family Office LLC now owns 163,500 shares of the medical technology company’s stock worth $1,499,000 after buying an additional 36,715 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in Inogen by 23.5% in the 4th quarter. Bank of New York Mellon Corp now owns 126,461 shares of the medical technology company’s stock worth $1,160,000 after purchasing an additional 24,082 shares in the last quarter. 89.94% of the stock is currently owned by institutional investors.

Inogen Stock Performance

Shares of INGN stock opened at $7.25 on Wednesday. The company has a market capitalization of $192.34 million, a price-to-earnings ratio of -3.22 and a beta of 1.15. The company’s 50-day moving average is $9.62 and its 200 day moving average is $9.61. Inogen, Inc. has a one year low of $6.14 and a one year high of $13.33.

Wall Street Analyst Weigh In

INGN has been the subject of a number of research analyst reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Inogen in a report on Wednesday, February 26th. StockNews.com lowered shares of Inogen from a “buy” rating to a “hold” rating in a report on Wednesday, February 26th.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.